Kidney disease deserves more innovation
It’s time to update our understanding of kidney disease, including reclassification based not simply on loss of kidney function, but...
In Support of the Dialysis PATIENTS Demonstration Act (PATIENTS Act)
The Dialysis PATIENTS Demonstration Act (PATIENTS Act) proposed Federal legislation will deliver high-quality, integrated care to patients receiving dialysis for...
ESCOs and QPs: Of Right Hands and Lefts
In an article for Acumen Physician Solutions, Dr. Terry Ketchersid illuminates the benefits of participating in an Advanced Alternative...
Transitioning from Part D to Part B: A Medicare Story
Author: Jeffrey L. Hymes, MD, CMO & SVP Following the U.S. Food and Drug Administration’s recent approval of Parsabiv™ (etelcalcetide),...
We Encourage Everyone to Say Thank You to a Nephrology Nurse
It takes a special kind of person to dedicate their life to taking care of others. Nephrology nurses help their...
Integrated pharmacy care linked to better patient outcomes
Patients on dialysis face a number of challenges including a heavy medication burden that often includes 10 to 12 routine...
Patient satisfaction is at an all-time high at FreseniusRx
Randell J. Correia, PharmD, FreseniusRx President FreseniusRx is proud to put patients first in all we do—our pharmacists focus specifically...
New President of FreseniusRx to Build on Company’s Success in Contributing to Positive Patient Outcomes
RJ Correia takes the helm as FreseniusRx’s pharmacy customers experience improved health measurements April 13, 2017 WALTHAM, Mass.–(BUSINESS WIRE)–FreseniusRx, a...
Intravenous Form of Sensipar® Has Been Approved by the FDA
Author: Jeffrey L. Hymes, MD, CMO & SVP Parsabiv™, an IV formulation similar to the oral calcimimetic Sensipar®, was recently...
Fresenius Medical Care Expands ESCO Participation
The Centers for Medicare & Medicaid Services recently announced the acceptance of 24 new markets into its ESRD Seamless Care...